Literature DB >> 9220634

Efficacy of an inactivated vaccine for prevention of reproductive failure induced by porcine reproductive and respiratory syndrome virus.

J Plana-Durán1, M Bastons, A Urniza, M Vayreda, X Vilà, H Mañé.   

Abstract

This report describes the results of experiments with an inactivated oily vaccine containing per dose about 10(5.5) median tissue culture infectious dose (TCID50) of the Spanish strain of porcine reproductive and respiratory syndrome (PRRS) virus grown in porcine alveolar macrophages (PAMs). In order to evaluate the efficacy of the vaccine, two experimental infection routes were tested in sows; subsequent intranasal (i.n.) and intravenous (i.v.) (out of a total of 93 piglets born to 7 sows, 16% were mummified, 18.2% were weak and died within 48 h of birth, 37% were stillborn, 5.3% died between 2 and 7 days of age, 22.5% lived for more than one week) and intranasal alone (out of a total of 65 piglets born to 5 sows, 0% were mummified, 22.5% were weak and died within 48 h of birth, 40% were stillborn, 4.6% lived for more than one week). I.N. alone was selected to evaluate the efficacy of the vaccine because this is the natural route of infection. A number of experiments were conducted to test the immunogenicity of the vaccine. In general, after challenge with the homologous strain, protection in vaccinated sows was high (at least 70% of the piglets were born alive and healthy), whereas protection in unvaccinated sows was low (only 10% of the piglets were born alive and healthy). Vaccinated animals devoid of antibodies by immunoperoxidase monolayer assay (IPMA) at the time of challenge were still protected at experimental infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220634     DOI: 10.1016/s0378-1135(96)01317-x

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Safety and efficacy of a novel European vaccine for porcine reproductive and respiratory virus in bred gilts.

Authors:  Michael D Piontkowski; Jeremy Kroll; Francois-Xavier Orveillon; Christian Kraft; Teresa Coll
Journal:  Can J Vet Res       Date:  2016-10       Impact factor: 1.310

2.  Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts.

Authors:  Taehwan Oh; Hanjin Kim; Kee Hwan Park; Jiwoon Jeong; Ikjae Kang; Siyeon Yang; Chanhee Chae
Journal:  Can J Vet Res       Date:  2019-10       Impact factor: 1.310

3.  Efficacy of an inactivated PRRSV vaccine: induction of virus-neutralizing antibodies and partial virological protection upon challenge.

Authors:  Gerald Misinzo; Peter L Delputte; Peter Meerts; Christa Drexler; Hans J Nauwynck
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

4.  The assessment of efficacy of porcine reproductive respiratory syndrome virus inactivated vaccine based on the viral quantity and inactivation methods.

Authors:  Hyunil Kim; Hye Kwon Kim; Jung Ho Jung; Yoo Jung Choi; Jiho Kim; Chang Gyu Um; Su Bin Hyun; Sungho Shin; Byeongchun Lee; Goo Jang; Bo Kyu Kang; Hyoung Joon Moon; Dae Sub Song
Journal:  Virol J       Date:  2011-06-27       Impact factor: 4.099

5.  Boosting in planta production of antigens derived from the porcine reproductive and respiratory syndrome virus (PRRSV) and subsequent evaluation of their immunogenicity.

Authors:  Robin Piron; Stefaan De Koker; Annelies De Paepe; Julie Goossens; Johan Grooten; Hans Nauwynck; Ann Depicker
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

Review 6.  Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development.

Authors:  X J Meng
Journal:  Vet Microbiol       Date:  2000-06-12       Impact factor: 3.293

Review 7.  Immune Control of PRRS: Lessons to be Learned and Possible Ways Forward.

Authors:  Massimo Amadori; Elisabetta Razzuoli
Journal:  Front Vet Sci       Date:  2014-10-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.